Akebia Therapeutics (AKBA) News Today → Does this chart look familiar? (From InvestorPlace) (Ad) Free AKBA Stock Alerts $1.29 +0.08 (+6.61%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 12:27 PM | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)May 10 at 4:25 PM | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call TranscriptMay 10 at 4:25 PM | finance.yahoo.comAkebia Therapeutics Reports Q1 2024 Financial Results: A Detailed OverviewMay 10 at 1:46 PM | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Releases Quarterly Earnings Results, Meets EstimatesAkebia Therapeutics (NASDAQ:AKBA - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The business had revenue of $32.61 million during the quarter, compared to the consensus estimate of $41.13 million. During the same quarter last year, the company earned ($0.14) EPS.May 10 at 11:22 AM | finance.yahoo.comAkebia Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 9, 2024 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comAKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | sfgate.comAkebia Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | americanbankingnews.comAkebia Therapeutics (AKBA) Scheduled to Post Earnings on ThursdayMay 3, 2024 | marketbeat.comAkebia Therapeutics (AKBA) Set to Announce Quarterly Earnings on ThursdayAkebia Therapeutics (NASDAQ:AKBA) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 2, 2024 | finanznachrichten.deAkebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | prnewswire.comAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsMay 1, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | stocknews.com4 Biotech Stocks to Watch Closely in MayApril 29, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.comStockNews.com downgraded Akebia Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.April 28, 2024 | finance.yahoo.comWhen Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?April 19, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Lifted to "Buy" at StockNews.comStockNews.com upgraded Akebia Therapeutics from a "hold" rating to a "buy" rating in a report on Friday.April 13, 2024 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Up 32.3% in MarchAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 13,400,000 shares, a growth of 32.3% from the March 15th total of 10,130,000 shares. Based on an average trading volume of 4,530,000 shares, the short-interest ratio is currently 3.0 days.April 11, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Downgraded by StockNews.comStockNews.com cut shares of Akebia Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday.April 3, 2024 | marketbeat.comAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemiaApril 3, 2024 | marketbeat.comAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentAkebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.April 3, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to BuyStockNews.com raised Akebia Therapeutics from a "hold" rating to a "buy" rating in a research report on Wednesday.March 29, 2024 | msn.comBiggest stock movers today: AMC, PLTR, RH, and moreMarch 28, 2024 | finance.yahoo.comFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated AnemiaMarch 28, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Price Target Raised to $6.00HC Wainwright upped their price objective on Akebia Therapeutics from $5.00 to $6.00 and gave the stock a "buy" rating in a research report on Thursday.March 28, 2024 | msn.comAkebia stock jumps as FDA clears renal anemia therapyMarch 28, 2024 | markets.businessinsider.comAkebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis PatientsMarch 28, 2024 | bizjournals.comTwo years after initial rejection, Akebia’s anemia drug finally gets FDA approvalMarch 27, 2024 | reuters.comU.S. FDA approves Akebia's anemia drugMarch 27, 2024 | prnewswire.comAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisMarch 27, 2024 | finance.yahoo.comAkebia Awaits FDA Word On Second Crack At VadadustatMarch 22, 2024 | marketbeat.comStock Traders Buy High Volume of Call Options on Akebia Therapeutics (NASDAQ:AKBA)Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of unusually large options trading activity on Friday. Traders acquired 6,762 call options on the company. This is an increase of 311% compared to the typical daily volume of 1,644 call options.March 19, 2024 | marketbeat.comInvestors Buy High Volume of Put Options on Akebia Therapeutics (NASDAQ:AKBA)Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) saw some unusual options trading activity on Tuesday. Stock traders acquired 2,369 put options on the stock. This represents an increase of approximately 74% compared to the average daily volume of 1,363 put options.March 18, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Rating Increased to Buy at StockNews.comStockNews.com raised shares of Akebia Therapeutics from a "hold" rating to a "buy" rating in a report on Monday.March 18, 2024 | marketbeat.comAkebia Therapeutics' (AKBA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Akebia Therapeutics in a research note on Friday.March 17, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33March 16, 2024 | finance.yahoo.comAkebia Therapeutics Full Year 2023 Earnings: EPS Beats ExpectationsMarch 15, 2024 | markets.businessinsider.comBuy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial PositionMarch 15, 2024 | finance.yahoo.comUS Life & Non-Life Insurance Market Poised for Strong Growth: In-Depth Analysis UnveiledMarch 14, 2024 | investorplace.comAKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023March 14, 2024 | benzinga.comRecap: Akebia Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comAkebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable QuarterMarch 14, 2024 | prnewswire.comAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 14, 2024 | markets.businessinsider.comAkebia Therapeutics earnings: here's what Wall Street expectsMarch 13, 2024 | benzinga.comEarnings Preview For Akebia TherapeuticsMarch 11, 2024 | finance.yahoo.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | prnewswire.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 1, 2024 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) COO Sells $13,684.38 in StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) COO Michel Dahan sold 8,661 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.58, for a total value of $13,684.38. Following the transaction, the chief operating officer now owns 706,932 shares in the company, valued at approximately $1,116,952.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.March 1, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. AKBA Media Mentions By Week AKBA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.390.57▲Average Medical News Sentiment AKBA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼143▲AKBA Articles Average Week Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VSTM News XOMA News FBLG News INZY News EPIX News NBTX News ELYM News RAPT News XBIT News XERS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
